Compare SPFI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPFI | CSTL |
|---|---|---|
| Founded | 1941 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 794.2M | 722.8M |
| IPO Year | 2019 | 2019 |
| Metric | SPFI | CSTL |
|---|---|---|
| Price | $44.75 | $28.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $46.00 | $45.50 |
| AVG Volume (30 Days) | 144.1K | ★ 290.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $22.65 | $2.42 |
| Revenue Next Year | $9.40 | $12.69 |
| P/E Ratio | $52.56 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $35.34 | $14.59 |
| 52 Week High | $46.94 | $44.28 |
| Indicator | SPFI | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 75.45 |
| Support Level | $39.06 | $22.67 |
| Resistance Level | $44.48 | $34.97 |
| Average True Range (ATR) | 1.37 | 1.31 |
| MACD | 0.02 | 0.33 |
| Stochastic Oscillator | 48.38 | 84.88 |
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.